<h2 dir="ltr">Invasive Fungal Infections Overview</h2>
Invasive Fungal Infections mainly occur in patients with compromised immune systems, encompassing individuals with conditions like cancer, HIV/AIDS, critical illness, systemic glucocorticoid use, organ transplants, and other severe underlying or respiratory diseases.
<h3 dir="ltr">Invasive Fungal Infections Epidemiology Segmentation</h3>
<ul>
<li dir="ltr" aria-level="1">
Total Incident Cases of Invasive Fungal Infections
</li>
<li dir="ltr" aria-level="1">
Total Incident Cases of Invasive fungal infections by type
</li>
<li dir="ltr" aria-level="1">
Total Treatment-eligible Cases of Invasive Fungal Infections
</li>
<li dir="ltr" aria-level="1">
Total Refractory Cases of Invasive Fungal Infections
</li>
</ul>
<h3 dir="ltr">Invasive Fungal Infections Epidemiology&nbsp;</h3>
<ul>
<li dir="ltr" aria-level="1">
The global incidence of IFIs is rising with the expanding at-risk population; the US burden was estimated at 110,000 cases in 2024 and is projected to increase through 2034.
</li>
<li dir="ltr" aria-level="1">
Invasive candidiasis and aspergillosis are the largest group of opportunistic IFIs, primarily affecting immunocompromised patients and contributing around 50% of the total burden.
</li>
<li dir="ltr" aria-level="1">
Histoplasmosis and coccidioidomycosis form a major portion of the endemic pool, with histoplasmosis cases showing a steady increase.
</li>
<li dir="ltr" aria-level="1">
Approximately 90% of patients develop resistance to first-line antifungal therapy, and nearly 30% of those also become resistant to second-line agents, requiring complex therapy modification and class switching.
</li>
</ul>
<h3 dir="ltr">Invasive Fungal Infections Market</h3>
<ul>
<li dir="ltr" aria-level="1">
The total market size for IFIs in the US was approximately $352 million in 2024 and is projected to increase during the 2025&ndash;2034 forecast period.
</li>
<li dir="ltr" aria-level="1">
DelveInsight analysis projects that fosmanogepix is expected to generate the highest revenue among emerging therapies in the United States by 2034.
</li>
</ul>
<h3 dir="ltr">Invasive Fungal Infections Market Drivers&nbsp;</h3>
<ul>
<li dir="ltr" aria-level="1">
The increasing patient pool is large and expanding, driven by the rising number of immunocompromised individuals across various groups, including transplant, oncology, ICU, HIV/AIDS, diabetes, and steroid users.
</li>
<li dir="ltr" aria-level="1">
Unmet need for rapid diagnostics and early detection tools that can shorten the time to therapy and reduce mortality.
</li>
</ul>
<h3 dir="ltr">Invasive Fungal Infections Market Barriers</h3>
Generic competition from established drugs (voriconazole, itraconazole, micafungin, amphotericin B) heavily impacts and reduces branded revenues.
<h3 dir="ltr">Emerging Invasive Fungal Infections Drugs</h3>
<ul>
<li dir="ltr" aria-level="1">
BREXAFEMME (Ibrexafungerp)
</li>
<li dir="ltr" aria-level="1">
Fosmanogepix
</li>
<li dir="ltr" aria-level="1">
Olorofim
</li>
<li dir="ltr" aria-level="1">
Opelconazole
</li>
<li dir="ltr" aria-level="1">
Oteseconazole (VT-1161)
</li>
<li dir="ltr" aria-level="1">
MAT2203, and others
</li>
</ul>
<h3 dir="ltr">Key Invasive Fungal Infections Companies</h3>
<ul>
<li dir="ltr" aria-level="1">
Cidara Therapeutics
</li>
<li dir="ltr" aria-level="1">
Mundipharma
</li>
<li dir="ltr" aria-level="1">
Astellas Pharma
</li>
<li dir="ltr" aria-level="1">
Pfizer&nbsp;
</li>
<li dir="ltr" aria-level="1">
Vicuron Pharmaceuticals&nbsp;
</li>
<li dir="ltr" aria-level="1">
Mayne Pharma&nbsp;
</li>
<li dir="ltr" aria-level="1">
Merck&nbsp;
</li>
<li dir="ltr" aria-level="1">
Glaxosmithkline&nbsp;
</li>
<li dir="ltr" aria-level="1">
Basilea Pharmaceutica&nbsp;
</li>
<li dir="ltr" aria-level="1">
F2G
</li>
<li dir="ltr" aria-level="1">
Pulmocide&nbsp;
</li>
<li dir="ltr" aria-level="1">
Mycovia pharmaceuticals&nbsp;
</li>
<li dir="ltr" aria-level="1">
Matinas BioPharma, and others
</li>
</ul>

Invasive Fungal Infections 

Invasive Fungal Infections Infographic

Invasive Fungal Infections Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape